Respiratory surveillance report

The Public Health Agency (PHA) has integrated influenza, respiratory syncytial virus (RSV) and COVID-19 reporting into this report to provide a single overview of the epidemiology of these infections in Northern Ireland (NI), along with the number of respiratory care home outbreaks, hospital admissions and occupancy, and deaths. It offers references to additional sources of information for further details.

1 Summary

In week 13, influenza activity increased across all surveillance indicators. Respiratory syncytial virus (RSV) increased slightly across some surveillance indicators and remains at low levels. COVID-19 activity increased across the majority of indicators.

  • There were 125 unique episodes of influenza identified (two were typed as Flu A (H1), one was Flu A (H3), 44 were Flu A (not subtyped) and 78 were Flu B). For RSV, there were 11 unique episodes identified and for COVID-19 there were 37 unique episodes identified.

  • There were 1,569 total influenza tests (8.1% positivity) and 954 total RSV tests (1.2% positivity) performed. For COVID-19, there were 1,560 tests performed (2.5% positivity).

  • The GP influenza/flu-like-illness (flu/FLI) consultation rate was 6.1 per 100,000 population. The GP acute respiratory infection (ARI) consultation rate was 99.1 per 100,000 population.

  • There was one COVID-19 outbreak reported in a care home setting to The Public Health Agency (PHA) Health Protection acute response duty room.

  • Of the 66 new admissions, 22 were Flu A, 28 were Flu B, one was RSV and 15 were COVID-19.

  • Community-acquired emergency influenza and COVID-19 inpatients have increased whilst RSV inpatients have remained stable.

 

2 Virology surveillance

2.1 Episodes of influenza, RSV and COVID-19

The number of new influenza episodes increased in week 13, with 125 unique episodes identified. There were 113 episodes reported in week 12. The number of new RSV episodes increased in week 13, with 11 unique episodes identified. There were five episodes reported in week 12 (Figure 2.1).

Influenza and RSV episode rates by age groups are shown in (Figure 2.2). The highest influenza episode rate in week 13 was in the 0-4 age group (23.0 per 100,000 population). The highest RSV episode rate was in the 75+ age group (2.6 per 100,000 population).

Influenza rates across local government districts (LGD) are shown in (Figure 2.3). Armagh City, Banbridge and Craigavon had the highest influenza rate in week 13 (14.1 per 100,000 population). The highest RSV rate was in Causeway Coast and Glens (2.1 per 100,000 population).

The number of new COVID-19 episodes increased in week 13, with 37 unique episodes identified compared with 18 in week 12 (Figure 2.1).

COVID-19 episode rates by age groups are shown in (Figure 2.2). The highest COVID-19 episode rate in week 13 was in the 75+ age group (14.5 per 100,000 population).

COVID-19 episode rates across LGD are shown in (Figure 2.3). Armagh City, Banbridge and Craigavon had the highest COVID-19 episode rate in week 13 (4.1 per 100,000 population).

Supplementary tables of key figures are shown at the end of this bulletin.

 

Weekly number of unique episodes of influenza, RSV and COVID-19 by epidemiological week

Figure 2.1: Weekly number of unique episodes of influenza, RSV and COVID-19 by epidemiological week

 

Weekly episode rates of influenza, RSV and COVID-19 per 100,000 population, by age group, by epidemiological week

Figure 2.2: Weekly episode rates of influenza, RSV and COVID-19 per 100,000 population, by age group, by epidemiological week

 

Weekly episode rates of influenza, RSV and COVID-19 per 100,000 population, by local government district, by epidemiological week

Figure 2.3: Weekly episode rates of influenza, RSV and COVID-19 per 100,000 population, by local government district, by epidemiological week

 

2.2 Testing and positivity (%)

In week 13 there were 1,569 total influenza tests, 127 of which were positive (8.1% positivity). This is an increase from week 12 (7.4% positivity) (Figure 2.4).

There were 954 total RSV tests, 11 of which were positive (1.2% positivity). This is an increase compared with week 12 (0.5% positivity) (Figure 2.4).

There were 1,560 COVID-19 tests, 39 of which were positive (2.5% positivity). This is an increase compared with week 12 (1.2% positivity) (Figure 2.4).

Supplementary tables of key figures are shown at the end of this bulletin.

 

Weekly positivity for influenza, RSV and COVID-19, by epidemiological week

Figure 2.4: Weekly positivity for influenza, RSV and COVID-19, by epidemiological week

 

2.3 Influenza subtyping

Of the 125 new influenza episodes identified in week 13, two were typed as Flu A (H1), one was Flu A (H3), 44 were Flu A (not subtyped) and 78 were Flu B (Figure 2.5).

 

Weekly number of unique episodes of influenza, by subtype and epidemiological week

Figure 2.5: Weekly number of unique episodes of influenza, by subtype and epidemiological week

 

2.4 Sentinel surveillance

Sentinel surveillance plays a role in monitoring and understanding the spread and impact of respiratory viruses like influenza and COVID-19 in the community. It involves a systematic and targeted approach to collect data from a geographical representative subset of GP practices (~18% population representative) to provide information about virus activity across NI.

In week 13, eight samples were positive for influenza from 26 samples submitted for testing (30.8% positivity) to the Regional Virus Laboratory (RVL). Two were for Flu A (not subtyped) and six were Flu B. One sample was positive for RSV from 26 samples submitted for testing (3.9% positivity). There were two positive COVID-19 sample from 26 samples (7.7% positivity) submitted for testing. (Table 1).

Total sentinel cases of influenza, RSV and COVID-19 by age group for the previous year are shown in (Figure 2.6), (Figure 2.7) and (Figure 2.8), and cumulatively for the 2024/25 influenza season in Table 2.

Supplementary tables of key figures are shown at the end of this bulletin.

 

Table 1. Total sentinel tests and positivity for Influenza, RSV and COVID-19, current week

 

 

Total Tests

Total Positives

Positivity (%)

2025 - 13

Influenza

26

8

30.77

2025 - 13

RSV

26

1

3.85

2025 - 13

COVID-19

26

2

7.69

 

Weekly sentinel influenza cases, by age group, by epidemiological week

Figure 2.6: Weekly sentinel influenza cases, by age group, by epidemiological week

 

Weekly sentinel RSV cases, by age group, by epidemiological week

Figure 2.7: Weekly sentinel RSV cases, by age group, by epidemiological week

 

Weekly sentinel COVID-19 cases, by age group, by epidemiological week

Figure 2.8: Weekly sentinel COVID-19 cases, by age group, by epidemiological week

 

Table 2. Total sentinel cases of Influenza, RSV and COVID-19 by age group, Week 40 - current week, 2024/25

 

0-4

5-14

15-44

45-64

65-74

75+

Total

Flu A (H1)

27

22

96

61

23

23

252

Flu A (H3)

2

3

10

6

3

1

25

Flu A (not subtyped)

5

1

22

12

1

5

46

Flu B

6

9

86

13

1

1

116

RSV

18

4

13

13

8

9

65

COVID-19

0

0

5

3

4

10

22

 

2.5 Non-sentinel surveillance

Non-sentinel surveillance is the monitoring of respiratory viruses from virology data collected from settings such as hospitals and GPs (excluding the sentinel GPs). This provides information about virus activity across NI.

In week 13, 119 samples were positive for influenza from 1,543 samples submitted for testing to laboratories across NI (7.7% positivity). Two were typed as Flu A (H1), two were Flu A (H3), 42 were Flu A (not subtyped), and 73 were Flu B. 10 samples were positive for RSV from 928 samples submitted for testing (1.1% positivity). 37 samples were positive for COVID-19 from 1,534 samples submitted for testing (2.4% positivity) (Table 3).

Total non-sentinel cases of influenza, RSV and COVID-19 by age group for the previous year are shown in (Figure 2.6), (Figure 2.7) and (Figure 2.11), and cumulatively for the 2024/25 influenza season in Table 4.

Supplementary tables of key figures are shown at the end of this bulletin.

 

Table 3. Total non-sentinel tests and positivity for Influenza, RSV and COVID-19, current week

 

 

Total Tests

Total Positives

Positivity (%)

2025 - 13

Influenza

1,543

119

7.71

2025 - 13

RSV

928

10

1.08

2025 - 13

COVID-19

1,534

37

2.41

 

Weekly non-sentinel influenza cases, by age group, by epidemiological week

Figure 2.9: Weekly non-sentinel influenza cases, by age group, by epidemiological week

 

Weekly non-sentinel RSV cases, by age group, by epidemiological week

Figure 2.10: Weekly non-sentinel RSV cases, by age group, by epidemiological week

 

Weekly non-sentinel COVID-19 cases, by age group, by epidemiological week

Figure 2.11: Weekly non-sentinel COVID-19 cases, by age group, by epidemiological week

 

Table 4. Total non-sentinel cases of Influenza, RSV and COVID-19 by age group, Week 40 - current week, 2024/25

 

0-4

5-14

15-44

45-64

65-74

75+

Total

Flu A (H1)

416

155

263

395

276

737

2,242

Flu A (H3)

52

31

61

63

25

68

300

Flu A (not subtyped)

763

395

546

556

337

756

3,353

Flu B

279

224

543

84

22

43

1,195

RSV

1,329

34

62

108

127

284

1,944

COVID-19

125

33

127

224

294

748

1,551

 

2.6 SARS-CoV-2 variants

XEC is a recombinant lineage of KS.1.1 and KP.3.3 (both of which are JN.1 sub-lineages). The KP.3 and other KP lineages are descended from JN.1 sub-lineages, and they are now reported separately from JN.1 to illustrate the evolving genomic epidemiology. For the week commencing 23 December 2024, XEC accounted for 50.0% of all sequenced samples, KP.3 for 38.9%, and for JN.1 and KP both 5.6%, respectively. Due to small numbers of samples sequenced, the level of confidence in precision of the estimate is low, and the percentages of each variant may change as further results become available. A more detailed COVID-19 Genomics Bulletin containing a further breakdown of sub-lineages is published weekly. Technical information is published by UKSHA on some specific KP variants online.

Parent lineages displayed are subject to change based on lineages under monitoring by the UKHSA horizon scanning team.

 

Total number of sequenced variants of COVID-19 by Pangolin lineage, by epidemiological week

Figure 2.12: Total number of sequenced variants of COVID-19 by Pangolin lineage, by epidemiological week

Recombinant refers to any recombinant lineage, starting “X”, that does not fall under the parent lineage of a defined variant.

 

3 Primary care surveillance

3.1 Consultation rates for influenza/influenza-like-illness (‘flu/FLI’)

The general practice (GP) flu/FLI consultation rate during week 13 was 6.3 per 100,000 population. This is similar to week 12 (6.1 per 100,000 population). Rates are at baseline activity levels (<10.1 per 100,000 population) (Figure 3.1).

Flu/FLI consultation rates by age groups are shown in Table 5. The highest rate in week 13 was seen in the 0-4 age group (9.2 per 100,000 population).

Flu/FLI consultation rates by Health and Social Care Trust (HSCT) are shown in Table 6. The highest rate in week 13 was seen in the Southern Trust (7.7 per 100,000 population).

Since the beginning of the COVID-19 pandemic, the offer of uptake of GP consultations has changed. As a result, consultation rates in the most recent period are unlikely to be directly comparable to pre-pandemic and pandemic years.

 

Northern Ireland GP consultation rates for ‘flu/FLI’ 2021/22 – 2024/25

Figure 3.1: Northern Ireland GP consultation rates for ‘flu/FLI’ 2021/22 – 2024/25

The baseline MEM threshold for Northern Ireland is <10.1 per 100,000 population for 2024-25. Low activity is 10.1 to <20.5, moderate activity 20.5 to <47.4, high activity 47.4 to <68.5 and very high activity is >68.5 per 100,000 population.

 

Table 5. Flu/FLI consultation rates per 100,000 population, by age groups, over a six week period

 

0-4

5-14

15-44

45-64

65-74

75+

Total

2025 - 08

12.20

5.24

15.98

11.89

8.54

13.33

12.48

2025 - 09

11.17

5.19

13.57

9.97

5.95

10.28

10.50

2025 - 10

11.17

2.97

10.62

6.41

4.96

4.57

7.58

2025 - 11

8.34

6.28

9.86

6.55

4.43

6.81

7.72

2025 - 12

7.37

4.77

7.47

6.33

3.43

3.38

6.13

2025 - 13

9.16

3.64

8.55

5.75

1.45

4.47

6.25

 

Table 6. Flu/FLI consultation rates per 100,000 population, by Health and Social Care Trust, over a six week period

 

Belfast

Northern

Western

Southern

South Eastern

Northern Ireland

2025 - 08

8.65

10.23

12.14

15.64

17.37

12.48

2025 - 09

9.07

7.96

12.33

11.90

12.52

10.50

2025 - 10

8.86

7.01

9.25

6.53

6.39

7.58

2025 - 11

4.40

8.33

9.03

7.23

10.39

7.72

2025 - 12

6.70

4.17

7.80

7.23

5.24

6.13

2025 - 13

6.49

4.55

6.46

7.70

6.44

6.25

 

3.2 Consultation rates for acute respiratory infection (ARI)

The GP ARI consultation rate during week 13 was 116.8 per 100,000 population. This is an increase from week 12 (99.1 per 100,000 population) (Figure 3.2).

ARI consultation rates by age groups are shown in Table 7. The highest rate in week 13 was seen in the 0-4 age group (453.4 per 100,000 population).

ARI consultation rates by HSCT are shown in Table 8. The highest rate in week 13 was seen in the South Eastern Trust (135.4 per 100,000 population).

 

Northern Ireland GP consultation rates for ARI 2021/22 – 2024/25

Figure 3.2: Northern Ireland GP consultation rates for ARI 2021/22 – 2024/25

 

Table 7. ARI consultation rates per 100,000 population, by age groups, over a six week period

 

0-4

5-14

15-44

45-64

65-74

75+

Total

2025 - 08

463.43

122.50

99.94

107.73

126.12

146.66

129.10

2025 - 09

508.28

130.21

90.65

98.67

140.38

137.66

126.85

2025 - 10

504.66

132.86

89.21

89.57

121.95

134.72

122.11

2025 - 11

490.24

139.91

83.81

79.28

115.28

136.18

116.96

2025 - 12

389.85

105.33

76.12

70.01

104.27

109.43

99.06

2025 - 13

453.40

133.81

85.89

89.14

110.83

130.70

116.83

 

Table 8. ARI consultation rates per 100,000 population, by Health and Social Care Trust, over a six week period

 

Belfast

Northern

Western

Southern

South Eastern

Northern Ireland

2025 - 08

126.02

129.62

137.30

114.13

142.25

129.10

2025 - 09

130.85

132.06

134.52

99.18

138.80

126.85

2025 - 10

126.80

123.89

132.26

103.37

125.45

122.11

2025 - 11

110.53

121.79

135.48

103.36

115.87

116.96

2025 - 12

109.29

93.02

107.85

86.12

100.58

99.06

2025 - 13

110.96

110.07

133.91

99.43

135.40

116.83

 

4 Community surveillance

4.1 Influenza, RSV and COVID-19 care homes outbreaks

There was one COVID-19 outbreak reported in a care home setting in week 13. This is the same as week 12 (one COVID-19 outbreak reported) (Figure 4.1).

 

Weekly number of confirmed influenza, RSV and COVID-19 outbreaks, by year and epidemiological week

Figure 4.1: Weekly number of confirmed influenza, RSV and COVID-19 outbreaks, by year and epidemiological week

 

5 Secondary care surveillance

5.1 Admissions and occupancy

There were 66 new community-acquired emergency hospital admissions during week 13 (Figure 5.1). This is an increase from week 12 (n=42). Of the 66 new admissions, 22 were Flu A, 28 were Flu B, one was RSV and 15 were COVID-19.

The 5-14 age group had the majority of community acquired emergency influenza hospital admissions in week 13 (48.0%). The 75+ age group had the majority of COVID-19 hospital admissions (60.0%, respectively).

Community-acquired emergency influenza and COVID-19 inpatients have increased whilst RSV inpatients have remained stable. (Figure 5.2).

 

Weekly number of community-acquired emergency influenza, RSV and COVID-19 hospital admissions, by year and epidemiological week

Figure 5.1: Weekly number of community-acquired emergency influenza, RSV and COVID-19 hospital admissions, by year and epidemiological week

 

Influenza, RSV and COVID-19 community acquired emergency inpatients, by day

Figure 5.2: Influenza, RSV and COVID-19 community acquired emergency inpatients, by day

 

6 Mortality surveillance

6.3 Excess Mortality

NISRA use the UK-wide methodology to report on excess deaths as advised by the Office for National Statistics (ONS).

EuroMOMO is a European mortality monitoring activity, aiming to detect and measure excess deaths related to seasonal influenza, pandemics and other public health threats. Reports on excess deaths across Europe and the United Kingdom are published weekly.

 

7 Methods

7.1 Presentation of data

Unless otherwise stated, data are presented using epidemiological weeks (a standardised method of counting weeks [Monday-Sunday] to allow for the comparison of data year after year). This is dependent on the data available. The data included in this report are the most up to date data available at the time of the report; however, this is subject to change as the data are subject to ongoing quality assurance.

7.2 Virology surveillance

All virology data provided here are preliminary. Virology data for prior weeks, as included in this or future bulletins, are subject to updates based on laboratory returns received after the last report was produced. The current bulletin offers the most current information available.

Rates per 100,000 population are calculated using the NISRA 2021 Mid-Year Population Estimates.

7.2.1 Episodes of infection

Influenza

Influenza episodes are defined by a 42-day (6-week) period from the date of the first positive test result (utilising any test method, including PCR and Point of Care Tests, or source of sample, including hospital, GP, other source), with the episode beginning with the earliest positive specimen date. Subsequent positive specimen dates for the same individual within 42 days of the last are included in the one episode. Positive specimens for the same individual more than 42 days after the last are counted in a separate episode.

RSV

RSV episodes are defined by a 14-day (2-week) period from the date of the first positive test result (utilising any test method, including PCR and Point of Care Tests, or source of sample, including hospital, GP, other source), with the episode beginning with the earliest positive specimen date. Subsequent positive specimen dates for the same individual within 14 days of the last are included in the one episode. Positive specimens for the same individual more than 14 days after the last are counted in a separate episode.

COVID-19

COVID-19 episodes are defined by a rolling 90-day period between positive test results (any test method, sourced from the NI COVID-19 combined testing register), with the episode beginning with the earliest positive specimen date. Subsequent positive specimen dates for the same individual within 90 days of the last are included in the one episode. Positive specimens for the same individual more than 90 days after the last are counted in a separate episode.

7.2.2 Testing and positivity (%)

7.2.2.1 Influenza, RSV and COVID-19

Instead of utilising an episode-based approach, the data is analysed on an epidemiological week basis. Within each epidemiological week, an individual is limited to one influenza test, whether positive or negative. If an individual tests positive for influenza during a specific epidemiological week and subsequently tests positive again within the same week, the second positive test is not counted. Regardless of whether it occurs before or after a negative test within the same epidemiological week, a positive test always takes precedence and is recorded. Similarly, only the first test of multiple negative results is counted for each individual within any given epidemiological week. This helps prevent the double-counting of tests, particularly for individuals who may be hospitalised and routinely tested.

The same methodology is applied when analysing RSV and COVID-19 data.

7.2.2.2 Sentinel surveillance

The Public Health Agency works with GPs to deliver a community-based surveillance programme for respiratory infections in NI. The programme provides valuable intelligence about the circulation of respiratory viruses in NI to inform health and social care system planning and preparedness. Participation involves taking nasal/throat swabs from some symptomatic patients who agree to have a swab, and who attend (in person) with ILI, ARI or suspected COVID-19. Testing is opportunistic and within 10 days of symptom onset. Swabs are tested for influenza, RSV and COVID-19 at the RVL and surveillance is year-round.

7.2.2.3 SARS-CoV-2 genomics

A subset of SARS-CoV-2 positive PCR samples are sent to sequencing laboratories in Belfast Health and Social Care Trust and Queen’s University Belfast for sequencing. On 29th November the lineage assignment algorithm was switched from PangoLEARN to UShER for lineage counts. PangoLEARN uses a machine learning algorithm, whereas UShER uses phylogenetic placement and produces fewer unassigned lineages. This switch has been applied retrospectively, therefore total counts for all lineages have been affected. A more detailed COVID-19 Genomics Bulletin containing a further breakdown of sub-lineages is published weekly.

7.3 Primary care surveillance

7.3.1 Consultation rates for influenza/influenza-like-illness (‘flu/FLI’) and acute respiratory infection (ARI)

GP in-hours consultation data with ~95% coverage of the NI population is auto-extracted weekly from GPIP. This data includes weekly aggregate consultations for ‘flu/FLI’ and ARI, and includes weekly registered patients. The data is available for different Health and Social Care Trusts, and by age and sex.

7.4 Community surveillance

7.4.1 Care home outbreaks

PHA conducts surveillance of outbreaks across multiple settings, including care homes (nursing homes and residential homes) in NI that are registered with the Regulation and Quality Improvement Agency. All care homes have a requirement to notify the PHA Health Protection duty room of suspected outbreaks of any infectious disease. A confirmed outbreak of influenza or RSV can be defined as where there are two or more confirmed cases with onset within a 14 day period, where transmission within the Care Home facility is considered the likely cause.

7.5 Secondary care surveillance

7.5.1 Admissions and occupancy

Where it is currently possible (SHSCT and WHSCT) only admissions where the method of admission was ‘Emergency’ are counted. It is not currently possible for this report to distinguish emergency from other types of admission for SEHSCT, BHSCT and NHSCT hospital data, following the introduction of a new electronic healthcare record on 06/11/2023, 06/06/2024 and 07/11/2024 respectively. For this report, all community-acquired admissions for SEHSCT, BHSCT and NHSCT are included, which will include non-emergency admissions (which are a small minority of the total admissions reported). Work is ongoing to adapt systems to new data sources and re-instate differentiation of emergency admissions. Ongoing developmental and quality assurance work may result in adjustments to figures.

7.5.1.1 Influenza and RSV

Community-acquired influenza and RSV emergency admissions to acute hospitals are estimated by combining data from PAS and virological reports in NIHAP. Admissions are counted where there was a positive test up to seven days before admission or up to one day after admission, and the method of admission was ‘Emergency’. The number of inpatients is counted at midnight. Admissions and occupancy refer to the first admission per infection episode.

7.5.1.2 COVID-19

Community-acquired COVID-19 emergency admissions are estimated by combining data from the NI COVID-19 Combined Testing Register and hospital admission information. Admissions are counted where there was a positive PCR or lateral flow test up to 14 days before admission or up to one day after admission. The number of inpatients is counted at midnight. Admissions and occupancy refer to the first admission per infection episode, including transfers between hospitals. The method used in this report is different to that previously reported by the Department of Health’s COVID-19 dashboard, which used administrative coding to identify COVID-19 admissions.

7.6 Mortality surveillance

NISRA death statistics are published weekly, and include weekly counts of deaths related to influenza and/or pneumonia (new from 31 January 2025), and deaths related to COVID-19. This enables comparisons with weekly information published by the Office for National Statistics (ONS) covering England and Wales.

The statistics report on deaths where influenza and/or pneumonia, or COVID-19, was mentioned anywhere on the death certificate. As a result, the counts will reflect deaths where these diseases have contributed to a death but was not necessarily the underlying cause of the death.

8 Supplementary tables

8.1 Unique episodes of influenza, RSV and COVID-19, by epidemiological week, over a six week period

Year and week

 

Unique episodes

2025 - 08

Influenza A

94

2025 - 08

Influenza B

116

2025 - 08

RSV

19

2025 - 08

COVID-19

21

2025 - 09

Influenza A

33

2025 - 09

Influenza B

103

2025 - 09

RSV

13

2025 - 09

COVID-19

25

2025 - 10

Influenza A

60

2025 - 10

Influenza B

102

2025 - 10

RSV

15

2025 - 10

COVID-19

38

2025 - 11

Influenza A

32

2025 - 11

Influenza B

90

2025 - 11

RSV

8

2025 - 11

COVID-19

24

2025 - 12

Influenza A

33

2025 - 12

Influenza B

80

2025 - 12

RSV

5

2025 - 12

COVID-19

18

2025 - 13

Influenza A

47

2025 - 13

Influenza B

78

2025 - 13

RSV

11

2025 - 13

COVID-19

37

 

8.2 Influenza, RSV and COVID-19 episode rates per 100,000 population, by age group, over a six week period

 

 

8.3 Influenza, RSV and COVID-19 episode rates per 100,000 population, by local government district, over a six week period

 

 

8.4 Total tests and positivity for influenza, RSV and COVID-19, by epidemiological week, over a six week period

Year and Week

 

Total Tests

Total Positives

Positivity (%)

2025 - 08

Influenza

1,819

211

11.60

2025 - 08

RSV

1,012

20

1.98

2025 - 08

COVID-19

1,804

26

1.44

2025 - 09

Influenza

1,603

143

8.92

2025 - 09

RSV

942

15

1.59

2025 - 09

COVID-19

1,596

27

1.69

2025 - 10

Influenza

1,671

167

9.99

2025 - 10

RSV

992

16

1.61

2025 - 10

COVID-19

1,660

34

2.05

2025 - 11

Influenza

1,600

126

7.88

2025 - 11

RSV

925

8

0.86

2025 - 11

COVID-19

1,603

27

1.68

2025 - 12

Influenza

1,579

116

7.35

2025 - 12

RSV

920

5

0.54

2025 - 12

COVID-19

1,574

19

1.21

2025 - 13

Influenza

1,569

127

8.09

2025 - 13

RSV

954

11

1.15

2025 - 13

COVID-19

1,560

39

2.50

 

8.5 Total sentinel tests and positivity for influenza, RSV and COVID-19, by epidemiological week, over a six week period

Year and Week

 

Total Tests

Total Positives

Positivity (%)

2025 - 08

Influenza

36

19

52.78

2025 - 08

RSV

36

0

0.00

2025 - 08

COVID-19

36

0

0.00

2025 - 09

Influenza

32

8

25.00

2025 - 09

RSV

32

0

0.00

2025 - 09

COVID-19

32

1

3.12

2025 - 10

Influenza

25

10

40.00

2025 - 10

RSV

25

0

0.00

2025 - 10

COVID-19

25

0

0.00

2025 - 11

Influenza

31

5

16.13

2025 - 11

RSV

31

0

0.00

2025 - 11

COVID-19

31

0

0.00

2025 - 12

Influenza

21

5

23.81

2025 - 12

RSV

21

0

0.00

2025 - 12

COVID-19

21

1

4.76

2025 - 13

Influenza

26

8

30.77

2025 - 13

RSV

26

1

3.85

2025 - 13

COVID-19

26

2

7.69

 

8.6 Total non-sentinel tests and positivity for influenza, RSV and COVID-19, by epidemiological week, over a six week period

Year and Week

 

Total Tests

Total Positives

Positivity (%)

2025 - 08

Influenza

1,783

192

10.77

2025 - 08

RSV

976

20

2.05

2025 - 08

COVID-19

1,768

26

1.47

2025 - 09

Influenza

1,571

135

8.59

2025 - 09

RSV

910

15

1.65

2025 - 09

COVID-19

1,564

26

1.66

2025 - 10

Influenza

1,646

157

9.54

2025 - 10

RSV

967

16

1.65

2025 - 10

COVID-19

1,635

34

2.08

2025 - 11

Influenza

1,569

121

7.71

2025 - 11

RSV

894

8

0.89

2025 - 11

COVID-19

1,572

27

1.72

2025 - 12

Influenza

1,558

111

7.12

2025 - 12

RSV

899

5

0.56

2025 - 12

COVID-19

1,553

18

1.16

2025 - 13

Influenza

1,543

119

7.71

2025 - 13

RSV

928

10

1.08

2025 - 13

COVID-19

1,534

37

2.41

 

8.7 Number of sequenced samples for variants in Northern Ireland

Parent Lineage

Cumulative Number Sequenced

BA.2

17

BA.3

29

EG.5.1

1

JN.1

134

KP

71

KP.3

598

LP.8.1

10

Unassigned

239

XBB

1

XEC

141

XEC.2

27

XEC.4

4

XEC.5

4

XEC.8

1

This table only shows counts for lineages with 10 or more sequenced samples from epidemiological year-week 2024 - 13 onwards. Lineage counts include provisional and confirmed sequencing samples. Lineage calls are subject to change following analysis of genomic sequence results, which may result in fluctuations in lineage counts.